IRVINE, Calif.--(BUSINESS WIRE)--BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on September 1, 2017 it named Jonathan “Jack” T. Lord, M.D., a nationally recognized leader in healthcare innovation, as its new Chairman of the Board. Dr. Lord replaces outgoing Chairman Paul N. Clark, who resigned from the Board of Directors effective September 11, 2017, due to other time commitments.
Dr. Lord, 62, was appointed to the BIOLASE Board in August 2014 and serves as Chairman of the Company’s Compensation Committee and a member of the Nominating and Corporate Governance Committee. He is a board-certified forensic pathologist and Fellow of the College of American Pathologists. Dr. Lord’s focus is on the commercialization of disruptive innovations that change people lives, which includes his relationships with such companies as Health Dialog, Humana, Therasense, Stericycle, Mako Surgical and Dexcom.
“Jack brings extensive innovation, executive management and board experience to his new role of Chairman of the Board of BIOLASE,” Mr. Clark said. “I have enjoyed working with the Company and serving as its Chairman of the Board. Under the leadership of Jack and President and CEO Harold Flynn, I believe the Company’s future is in good hands.”
Dr. Lord commented, “Paul has made important and significant contributions to BIOLASE, both as a leader and as a significant investor. We thank Paul for his valuable assistance and for his personal commitment to BIOLASE.”
From August 2011 to January 2013, Dr. Lord was affiliated with the University of Miami serving as Chief Operating Officer of its Leonard M. Miller School of Medicine and the Uhealth-University of Miami Health System, a healthcare network in south Florida. He was also the University’s Chief Innovation Officer. Previously he was President and Chief Executive Officer of Navigenics, Inc., a privately held healthcare company. Before that he was a senior executive at the Anne Arundel Medical Center and SunHealth, the American Hospital Association and Humana Inc. Dr. Lord serves or has served on the boards of several public and private healthcare companies. He began his medical career in the U.S. Navy, and received a Bachelor of Science degree in Chemistry and a Doctor of Medicine degree from the University of Miami. He has earned certificates in Governance and Audit from Harvard Business School.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 210 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 34,900 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.
For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding expected effects of the April 2017 financing and anticipated growth. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE’s annual and quarterly reports filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.